Patent · US Active

Composition for treatment of essential thrombocythemia

US9782413B2 · kind B2 · utility

0Cited by

1References

9Claims

0Family size

Assignee

AOP Orphan Pharmaceuticals AG · AT

Inventors

Rudolf Widmann · Purkersdorf, AT
Georg STRIEDER · Wien, AT

Key dates

Filing date	Oct 21, 2016
Grant date	Oct 10, 2017
Priority date	—
Expiry date	Oct 21, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2054
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid and its use for the treatment of essential thrombocythemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.